Table 2.
Hazard Ratios and 95% Confidence Intervals for the association between body mass index and endometrial cancer risk in the aggregated sample of postmenopausal Caucasian women stratified by parity and menopausal hormone therapy use: subset of women who reported never or current menopausal hormone therapy use at entry into NIH-AARP or after 1995 in PLCO and USRT
| Nulliparous women | Parous women | ||||
|---|---|---|---|---|---|
| Cases | HRs (95% CIs)a | Cases | HRs (95% CIs)a,b | P heterogeneity c | |
| Body mass index among never users of menopausal hormone therapy | |||||
| <25 kg/m2 | 23 | 1.00 (Referent) | 86 | 1.00 (Referent) | |
| 25–<30 kg/m2 | 30 | 1.87 (1.09, 3.23) | 125 | 1.73 (1.31, 2.27) | |
| ≥30 kg/m2 | 80 | 5.59 (3.46, 9.01) | 315 | 5.48 (4.30, 7.00) | 0.96 |
| Body mass index among current users of menopausal hormone therapy | |||||
| <25 kg/m2 | 45 | 1.00 (Referent) | 200 | 1.00 (Referent) | |
| 25–<30 kg/m2 | 32 | 1.36 (0.86, 2.14) | 113 | 1.00 (0.79, 1.26) | |
| ≥30 kg/m2 | 24 | 1.72 (1.03, 2.89) | 67 | 1.25 (0.94, 1.65) | 0.39 |
HRs: Hazard Ratios; 95% Confidence Intervals; Separate models fit to nulliparous and parous women. Models adjusted for age at menarche, age at menopause, oral contraceptive use as well as birth year, study, calendar year of entry, diabetes, and smoking status.
Further adjusted for number of births.
P-value for the heterogeneity between parous and nulliparous women based on a Wald type chi-square test.